New Agents to Prevent Strokes in Nonvalvular Atrial Fibrillation




Anticoagulation for atrial fibrillation has been dependant on warfarin for the past 30 years. However, the recent FDA approvals of dabigatran and rivaroxaban and the expected approval for apixaban have provided several new alternatives for our patients. Many factors must be considered when selecting the most appropriate agent for preventing stroke in nonvalvular atrial fibrillation. The following trials have provided the foundation for decision making when considering alternatives to warfarin therapy.


nonvalvular atrial fibrillationanticoagulationdabigatranrivaroxabanapixaban
  • Year: 2012
  • Volume: 8 Issue: 3
  • Page/Article: 44-46
  • DOI: 10.14797/mdcj-8-3-44
  • Published on 1 Jul 2012
  • Peer Reviewed